How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer
ABSTRACT Introduction: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian
target of rapamycin (PI3K/AKT/mTOR) pathway is a fundamental regulator of cell …
target of rapamycin (PI3K/AKT/mTOR) pathway is a fundamental regulator of cell …
Understanding monoclonal B cell lymphocytosis: an interplay of genetic and microenvironmental factors
C Galigalidou, L Zaragoza-Infante, A Iatrou… - Frontiers in …, 2021 - frontiersin.org
The term monoclonal B-cell lymphocytosis (MBL) describes the presence of a clonal B cell
population with a count of less than 5× 109/L and no symptoms or signs of disease. Based …
population with a count of less than 5× 109/L and no symptoms or signs of disease. Based …
Targeting the mutational landscape of bystander cells: drug-promoted blood cancer from high-prevalence pre-neoplasias in patients on BRAF inhibitors
D Simnica, H Ittrich, C Bockemeyer, A Stein… - Frontiers in …, 2020 - frontiersin.org
Drug-promoted cancers are increasingly recognized as a serious clinical problem in patients
receiving BRAF inhibitory treatment. Here we report on a patient with BRAF mutant hairy cell …
receiving BRAF inhibitory treatment. Here we report on a patient with BRAF mutant hairy cell …
[HTML][HTML] The potential differential diagnosis value and clinical significance of CD35 expression in B-chronic lymphoproliferative disorders
Y Shi, L Liu, H Yang, X Chen, Y Wang… - Annals of …, 2021 - ncbi.nlm.nih.gov
Background Flow cytometry for immunophenotyping is the main method for diagnosing
chronic lymphocytic leukemia (CLL). Differential diagnosis between CLL and other B …
chronic lymphocytic leukemia (CLL). Differential diagnosis between CLL and other B …
[PDF][PDF] Are Chronic lymphocytic leukemia blood parameters differing from Other leukemias subtypes
EA Abuelfadol, MMM Abdalla, M Elsayid, A Abdula - 2023 - researchgate.net
Background: Adults widely acknowledge CLL as a prevalent lymphoproliferative disease, a
hematological malignancy. Thus, the objective of this study was to assess potential …
hematological malignancy. Thus, the objective of this study was to assess potential …
Investigation of mutations, copy number variations and translocations by capture-based Next-generation sequencing in patients with chronic B-cell lymphoproliferative …
D Wren - 2021 - e-space.mmu.ac.uk
Patients with leukaemic indolent B-NHL who could not be assigned to a specific disease
category were identified and 108 cases underwent extensive molecular characterisation …
category were identified and 108 cases underwent extensive molecular characterisation …
ТЕРАПЕВТИЧНА ЕФИКАСНОСТ И РАЗХОДНА ЕФЕКТИВНОСТ НА IBRUTINIB/RITUXIMAB, IBRUTINIB/OBINUTUZUMAB И VENETOCLAX/OBINUTUZUMAB ЗА …
Т Веков, Н Чилингирова, Н Велева… - Medical Review …, 2021 - search.ebscohost.com
Целта на изследването е да се извърши моделиране на локални данни за разходи и
здравни ползи на алтернативните комбинирани терапии за лечение на пациенти с …
здравни ползи на алтернативните комбинирани терапии за лечение на пациенти с …
Therapeutic efficiency and cost effectivenes of ibrutinib/rituximab, ibrutinib/obinutuzumab and venetoclax/obinutuzumab for the treatment of patients with chronic …
T Vekov, N Chilingirova, N Veleva, M Vlahova - 2021 - cabidigitallibrary.org
The aim of the study is to model local data on the costs and health benefits of alternative
combination therapies for the treatment of patients with CLL and to make an indirect …
combination therapies for the treatment of patients with CLL and to make an indirect …